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Abstract
Background: Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease. Kunxian capsule, a
Chinese patent medicine which has been used in the treatment of immunologic diseases for many years in China,
has anti-inflammatory and immunoregulatory effects. This study investigates the efficacy and safety of Kunxian
capsules in the treatment of AS.
Method: This was a randomized, double-blind, parallel control clinical trial involving 80 patients with AS who
fulfilled the modified New York criteria (1984) and had active disease defined by a Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) ≥40 mm under background stable nonsteroidal anti-inflammatory drugs (NSAIDs)
for more than 4 weeks. Patients were randomly divided into two groups, the Kunxian group and the placebo
group, and Kunxian (0.6 g, three times per day) and the placebo were provided for 12 weeks. The primary endpoint
was the Assessment of SpondyloArthritis international Society (ASAS) 20 response rate at week 12. The secondary
endpoints were ASAS 40, BASDAI 50, the Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing
Spondylitis Metrology Index (BASMI), and Ankylosing Spondylitis Disease Activity Score on the basis of C-reactive
protein level (ASDAS-CRP) at weeks 2, 6, and 12.
Results: The primary endpoint of ASAS 20 at week 12 was achieved in 13 of 35 patients (37.1 %) among the
Kunxian group, compared with 4 of 33 (12.1 %) in the placebo group (p < 0.05). Significant improvement (BASDAI
50) was also observed between the Kunxian group and the placebo group at week 6 (14 (40 %) and 5 (15.5 %),
respectively, p < 0.05). At weeks 2, 6, and 12, the ASDAS-CRP level of the Kunxian group was significantly lower than
that of the placebo group, especially at week 6 (p < 0.01). Kunxian obviously reduced CRP levels compared to
placebo at weeks 2, 6, and 12 (p < 0.05). Compared with the placebo, Kunxian was associated with greater
improvements in signs and symptoms of patients with AS from the baseline to week 12, and significant intergroup
differences of additional composite indices of disease activity (i.e., erythrocyte sedimentation rate, patient global
assessment of disease activity, total back pain, level of morning stiffness, tender joints, and BASFI scores) were also
observed.
Conclusion: Kunxian capsule significantly decreased the disease activity of patients with AS.
Trial registration: NCT00953979. Registered on 5 August 2009.
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Background
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that affects the sacroiliac joint, spine bone pro-
trusion, and paraspinal soft tissue and peripheral joints;
it may also have extra-articular manifestations. In severe
cases, it can cause spinal deformity and ankylosis. Treat-
ment options available for AS are limited. Sulfasalazine
(SSZ), which has certain side effects, is one of the most
common treatments, and is mainly used in AS patients
with peripheral arthritis [1]. TNF-α receptor antagonists
are also used, but are very expensive [2]. Therefore, an
inexpensive drug with acceptable side effects is needed.
Kunxian capsule’s main component is triptolide [3],
which is extracted from the genus Tripterygium plant
Tripterygium hypoglaucum (levl.) Hutch. The genus
Tripterygium is from the Celastraceae plant family, and
different Tripterygium species have similar chemical
compositions and clinical efficacy [4]. Tripterygium has
been used in 21 autoimmune and inflammatory diseases
by rheumatologists in China since 1983 [5] to treat, e.g.,
rheumatoid arthritis (RA) [6, 7], systemic lupus erythe-
matosus (SLE) [8–10], and nephritis [10–13]. Since
2006, Kunxian capsule has been used in clinical settings
as an anti-inflammatory and immune system regulator
of RA [14–16], SLE [17], AS [18], and other inflamma-
tory and autoimmune diseases.
Although the therapeutic effect of Kunxian has been in-
vestigated in the treatment for patients with AS, the effect
has rarely been assessed by international indicators. This
study used the Assessment of SpondyloArthritis Inter-
national Society response rate 20/40/70 (ASAS 20/40/70),
Bath Ankylosing Spondylitis Disease Activity Index 20/50/
70 (BASDAI 20/50/70), Ankylosing Spondylitis Disease
Activity Score on the basis of C-reactive protein level
(ASDAS-CRP), Bath Ankylosing Spondylitis Functional
Index (BASFI), Bath Ankylosing Spondylitis Metrology
Index (BASMI), and other indices to measure the efficacy
of Kunxian capsules in the treatment of AS patients.
Methods
This study was approved by the Ethics Committee of the
Third Affiliated Hospital of Sun Yat-sen University and reg-
istered at ClinicalTrials.gov with identifier NCT00953979.
Patients
The patients with AS were those who visited the hos-
pital from December 2008 to February 2010, who were
aged from 18 to 65 years and living in China. They
were randomly divided into two groups according to a
random number table. AS patients who fulfilled the
modified New York criteria (1984) and had active dis-
ease defined by BASDAI ≥40 mm under background
stable nonsteroidal anti-inflammatory drugs (NSAIDs)
for more than 4 weeks were enrolled. Patients taking
disease-modifying antirheumatic drugs (DMARDs) or
biologics within 4 weeks before the study were ex-
cluded. Other exclusion criteria included intra-articular
injection within 3 months; history of heart failure, mul-
tiple sclerosis, chronic obstructive pulmonary disease,
recurrent infection, lymphoma, or other cancers; fibro-
myalgia or other rheumatic diseases; pregnant and lac-
tating women; previous poor compliance, mental
illness, and alcohol or drug addiction. The enrolled pa-
tients were not allowed to change background NSAID
dosage or add other anti-rheumatic drugs during the
study. After being informed of the details of the re-
search, all patients or their guardians provided written
informed consent to participate.
Fig. 1 Patient disposition. A total of 80 patients with AS were enrolled, among whom contact was lost in 7 patients (2 patients in Kunxian group
and 5 in placebo group), 2 patients exited for adverse events (one in Kunxian group and one in placebo group), and 2 patients had incomplete
information (one in Kunxian group and one in placebo group). Finally, 68 patients completed clinical observation throughout the 12 weeks (35 in
Kunxian group and 33 in placebo group)
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Intervention
Macroporous resin adsorption was used to prepare the
Kunxian. The preparation, quality control, and standard-
ized testing of Kunxian capsules and the placebo were
applied for and approved by China’s State Food and
Drug Administration and manufacturer (approval num-
ber: YBZ07522006-2009Z; 1514062). In the Kunxian
group, two Kunxian capsules (0.3 g/capsule, with a trip-
tolide content of 25 μg/capsule) were taken orally three
times a day for 12 weeks.
Assessment
Patients were examined and evaluated at weeks 0, 2, 6, and
12. Clinical assessment was performed using indices of
BASDAI, BASFI, Bath AS Patient Global Score (BAS-G),
nocturnal back pain, general back pain, and morning stiff-
ness. Spinal motility was assessed by chest expansion and
the Schober test. Laboratory tests for erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), blood
urea nitrogen, and serum creatinine were carried out. Ad-
verse events and concomitant medications were recorded.
The primary endpoint of efficacy was the proportion of pa-
tients who achieved ASAS 20 according to the Assessment
of SpondyloArthritis International Society (ASAS). The
secondary endpoints of efficacy were ASAS 40, BASDAI
50, and ASDAS-CRP calculated according to the following
formula: ASDAS-CRP = 0.121 × back pain + 0.058 ×morn-
ing stiffness duration + 0.11 × overall patient discomfort
degree + 0.073 × peripheral joint pain or swelling degree +
0.579 × Ln(CRP + 1).
Statistical analysis
The sample size was calculated based on findings of the
previous clinical studies in patients with AS. For the pri-
mary endpoint, a sample size of 10 patients per protocol
analysis set in each treatment group was required ac-
cording to 90 % statistical power based on a one-sided
test at 0.05. Thus, a target sample size of 40 patients per
treatment group was estimated with a drop-out rate of
20 %. Missing data were imputed using the last observa-
tion carried forward (LOCF) method. Data were pre-
sented as mean ± standard deviation (SD). All analyses
were performed by using the Statistical Package for the
Social Sciences for Windows (SPSS), version 13.0 and
Microsoft Office Excel. Categorical data (such as ASAS
20/40/70 and BASDAI 20/50/70) were expressed as
numbers or percentages and analyzed using the chi-
square test or Fisher’s exact probabilities. The t test was
used to investigate the difference in clinical parameters
such as BASFI, ASDAS-CRP, BASMI, CRP, and ESR.
Any p values less than 0.05 were considered statistically
significant.
Results
Disposition and characteristics of the patients
A total of 80 patients with a mean age of 31.9 ±
11.7 years were randomly divided into two groups, the
Kunxian group (40 patients) and the placebo group (40
patients) (Fig. 1). Among the 80 patients, 79 (98.78 %)
had inflammatory spinal pain. There were no statistical
differences in the baseline characteristics between the
Kunxian group and the placebo group (Table 1). The
distribution of demographical characteristics of the par-
ticipants is shown in Table 1. No differences between
variables were observed.
Efficacy
The primary endpoint of ASAS 20 at week 12 was achieved
in 13 of 35 patients (37.1 %) in the Kunxian group, com-
pared with 4 of 33 (12.1 %) in the placebo group (p < 0.05)







Male, n (%) 32 (91.4) 30 (90.9)
Age, years (SD) 27.19 (7.94) 28.83 (7.09)
Disease characteristics
Symptom duration in years 6.76 (5.47) 7.98 (4.78)
Concomitant NSAID, n (%) 13 (37.1) 15 (45.5)
Clinical features, n (%)
Inflammatory back pain 32 (91.4) 32 (97.0)
Elevated CRP (>3 mg/liter) 31 (88.6) 24 (72.7)
Elevated ESR (male >20;
female >15 mm/h)
32 (91.4) 29 (87.9)
Disease activity
ASDAS-CRP 3.36 (1.06) 3.41 (1.00)
BASDAI (0–10) 4.79 (1.45) 4.82 (1.22)
Total back pain (0–10) 5.09 (2.69) 5.34 (2.58)
Global assessment (0–10) 5.18 (2.08) 5.90 (1.85)
Swollen joints, range 0–44 0.46 (1.48) 0.29 (1.1)
Tender joints, range 0–44 5.57 (4.96) 4.91 (3.37)
BASFI (0–10) 3.10 (2.00) 2.80 (2.00)
Inflammation/morning
stiffness (0–10)
4.79 (2.79) 5.2 (2.43)
ESR (mm/h) 36.95 (25.26) 35.79 (31.46)
CRP (mg/liter) 29.5 (29.93) 27.50 (29.69)
BASMI (0–10) 2.88 (1.95) 3.75 (1.99)
All values are expressed as mean (SD) unless otherwise indicated
Abbreviations: NSAID nonsteroidal anti-inflammatory drugs, CRP C-reactive pro-
tein, ESR erythrocyte sedimentation rate, ASDAS Ankylosing Spondylitis Disease
Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, VAS
visual analog scale, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI
Bath Ankylosing Spondylitis Metrology Index
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(Fig. 2a). Significant improvements of BASDAI 50 were also
observed in the Kunxian-treated patients at week 6 (14
(40 %) and 5 (15.5 %), respectively, p < 0.05) (Fig. 2b). At
weeks 2, 6, and 12, the value of ASDAS-CRP in the Kun-
xian group was significantly lower than that in the placebo
group, especially at week 6 (p < 0.01) (Fig. 2c), indicating
that Kunxian obviously reduced CRP compared to the pla-
cebo (p < 0.05) at weeks 2, 6, and 12 (Fig. 2d).
Compared with the placebo, Kunxian was associated
with significantly greater improvements in signs and
symptoms of patients with AS from the baseline to week
12, and significant intergroup differences were also ob-
served in terms of additional composite indices of dis-
ease activity (i.e., BASFI, ESR, patient global assessment
of disease activity, total back pain, level of morning stiff-
ness, tender joints, and BASMI scores) (Table 2).
Safety
There were 11 patients with adverse events, 8 in the
Kunxian group and 3 in the placebo group. The main
adverse events were mild to moderate elevation of trans-
aminase, dysmenorrhea, menopause, stomach burning
sensation, gastrointestinal discomfort, slightly decreased
WBC or platelets, mild urinary tract infection, and dry
throat. There was no significant difference in the num-
ber of patients between the two groups (Table 3). We
will disseminate the results of our study via presenta-
tions at international conferences and publications in
peer-reviewed journals. The study will be implemented
and reported in line with Standard Protocol Items for
Randomised Trials (Additional file 1).
Discussion
AS is a chronic inflammatory autoimmune disease. The ac-
tivity of AS reflects the level of inflammation, predicts prog-
nosis, and influences treatment decisions. Currently, the
most accepted and widely used indicators to assess the dis-
ease activity of AS are ASAS 20/40 and BASDAI [19]. Most
studies have utilized these indicators in the clinical research
of Kunxian [14, 18]. However, both indicators have been
self-administered by patients or physicians—directed ques-
tionnaires and objective measures of the disease activity are
not included. The whole spectrum of the disease activity of
AS is not reflected. The Ankylosing Spondylitis Disease
Activity Score on the basis of CRP (ASDAS-CRP) can as-
sess the disease activity and efficacy of different therapies in
AS. It has been primarily applied in different races and has
shown good clinical value [20–22]. Based on feasibility, the
a b
c d
Fig. 2 The changes of ASAS 20, BASDAI 50, ASDAS-CRP, and CRP at weeks 0, 2, 6, and 12 in the patients with ankylosing spondylitis treated with
Kunxian. a ASAS 20 in Kunxian group was significantly higher than that in placebo group at week 12 (p < 0.05). b BASDAI 50 in Kunxian group
was significantly higher than that in placebo group at week 6 (p < 0.001). c ASDAS-CRP in Kunxian group was significantly higher than that in placebo
group, especially at week 6 (p < 0.001). d The change of serum CRP in Kunxian and placebo groups. Serum CRP in Kunxian group was significantly
lower than that in placebo group at weeks 2, 6, and 12 (p < 0.05)
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ASDAS consisting of total back pain, duration of morning
stiffness, the BASDAI question on peripheral joints, patient
global score of disease activity, and CRP were selected as
the preferred ASDAS (ASDAS-CRP) [23]. However, in vitro
and animal model studies have shown that the genus Trip-
terygium possesses anti-inflammatory and immunosuppres-
sive properties, including suppression of proinflammatory
cytokine production [24, 25]. In this study, Kunxian demon-
strated better efficacy than a placebo in suppressing the
disease activity of patients with AS as assessed by ASAS 20,
BASDAI 50, ASDAS-CRP, and serum CRP as well as patient
global assessment of the disease activity, total back pain, level
of morning stiffness, tender joints, and BASFI score.
Although Kunxian had good efficacy in patients with
AS, and its main component, Tripterygium hypoglau-
cum (levl.) Hutch, had weaker toxicity and side effects
than Tripterygium wilfordii [26], some adverse events
were observed in this study, including mild to moderate
Table 2 Efficacy at weeks 2, 6, and 12
Activity index Time Mean ± SD change from the baseline
Kunxian, n = 35 Placebo, n = 33
BASDAI (0–10), mean (±SD) Week 2 -1.46 ± 1.61 -0.91 ± 1.31
Week 6 -1.98 ± 1.48a -0.10 ± 1.13
Week 12 -1.68 ± 1.70 -1.11 ± 1.17
BASFI (0–10), mean (±SD) Week 2 -0.52 ± 1.17 -0.15 ± 1.32
Week 6 -0.88 ± 1.18c -0.28 ± 1.27
Week 12 -0.75 ± 2.26 -0.01 ± 1.59
ASDAS-CRP, mean (±SD) Week 2 -0.84 ± 0.91b -0.05 ± 0.98
Week 6 -1.25 ± 0.95a -0.06 ± 0.70
Week 12 -1.08 ± 1.03b -0.11 ± 1.79
ESR (mm/h), mean (±SD) Week 2 -11.26 ± 16.38c 0.15 ± 9.48
Week 6 -16.26 ± 18.63b 0.71 ± 16.76
Week 12 -14.51 ± 22.65c 0.09 ± 16.50
CRP (ref 6 mg/l), mean (±SD) Week 2 -16.49 ± 21.12b 0.37 ± 16.55
Week 6 -20.66 ± 23.71b 1.07 ± 20.20
Week12 -18.50 ± 26.18c 0.76 ± 16.67
Level of morning stiffness, 0–10 cm VAS Week2 -2.56 ± 2.81c -0.88 ± 1.37
Week6 -2.10 ± 2.39c -0.78 ± 2.38
Week 12 -2.53 ± 2.60c -1.34 ± 1.67
Global assessment, 0–10 cm VAS Week 2 -1.29 ± 1.94 -0.54 ± 1.30
Week 6 -1.99 ± 2.10c -0.81 ± 1.31
Week 12 -1.69 ± 2.30 -0.85 ± 1.55
Total back pain, 0–10 cm VAS Week 2 -1.22 ± 1.99 -0.45 ± 1.60
Week 6 -1.97 ± 2.08c –0.81 ± 1.98
Week 12 -1.94 ± 2.17c -0.77 ± 1.57
Swollen joints, range 0–44 Week 2 -0.14 ± 0.42 0.14 ± 0.85
Week 6 -0.16 ± 0.5 -0.05 ± 0.34
Week 12 0 ± 0.82 -0.06 ± 0.34
Tender joints, range 0–44 Week 2 -1.19 ± 2.77 -0.35 ± 0.73
Week 6 -2.38 ± 3.66c -0.26 ± 1.24
Week 12 -2.89 ± 3.43c -0.36 ± 1.32
BASMI (0–10), mean (±SD) Week 2 -0.32 ± 0.94 -0.32 ± 0.97
Week 6 -0.49 ± 1.10 -0.14 ± 0.98
Week 12 -0.24 ± 1.09 -0.21 ± 0.95
aCompared with placebo group. p < 0.0001
bCompared with placebo group. p < 0.001
cCompared with placebo group. p < 0.05
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liver toxicity, decreased WBC or platelets, and gastro-
intestinal discomfort. These adverse events had also
been observed in the treatment of other diseases such as
RA [14] and refractory nephrotic syndrome [27]. Many
Chinese papers reported that the most severe side effect
of Tripterygium was infertility, although animal experi-
ments showed it had no significant effect on infertility
or teratogenicity in rats, embryos, or fetuses [28]. Only
one case of dysmenorrhea was observed in the study.
Tripterygium hypoglaucum (levl.) Hutch nourishes the
kidneys and strengthens the essence. The other three
medicines, Epimedium, Dodder, and Lycium Chinense,
mainly contain flavonoids. According to the theory of
traditional Chinese medicine, Epimedium and Dodder
can enhance kidney yang and Lycium Chinense can en-
hance kidney yin. In China these three medicines have
been used for thousands of years. Thus, Epimedium,
Lycium Chinense, and Dodder can inhibit the reproduct-
ive toxicity of Tripterygium hypoglaucum (levl.) Hutch
without affecting its anti-inflammatory and immunosup-
pressive effects (the theory of Chinese medicine con-
siders that the kidneys store the vital essence and
dominate reproduction). Good results were observed in
this study, but the impact of Kunxian on human repro-
ductive function remains to be further studied.
Conclusion
Kunxian capsules have better efficacy than a placebo in
decreasing the disease activity of patients with AS
assessed by international indicators ASAS 20, BASDAI
50, ASDAS-CRP, and serum CRP as well as by patient
global assessment of the disease activity, total back pain,
level of morning stiffness, tender joints, and BASFI
score.
Additional file
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